bs-5585R [Primary Antibody]
PRKCQ(Thr538) Polyclonal Antibody
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: PRKCQ Thr538

Modification Site: Thr538

Clonality: Polyclonal

Isotype: IgG

Entrez Gene: 5588

Swiss Prot: Q04759

Source: KLH conjugated synthetic phosphopeptide derived from human PRKCQ around the phosphorylation site of Thr538

Purification: Purified by Protein A.

Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Background:

Calcium-independent, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that mediates non-redundant functions in T-cell receptor (TCR) signaling, including T-cells activation, proliferation, differentiation and survival, by mediating activation of multiple transcription factors such as NF-kappa-B, JUN, NFATC1 and NFATC2. In TCR-CD3/CD28-co-stimulated T-cells, is required for the activation of NF-kappa-B and JUN, which in turn are essential for IL2 production, and participates to the calcium-dependent NFATC1 and NFATC2 transactivation. Mediates the activation of the canonical NF-kappa-B pathway (NFKB1) by direct phosphorylation of CARD11 on several serine residues, inducing CARD11 association with lipid rafts and recruitment of the BCL10-MALT1 complex, which then activates IKK complex, resulting in nuclear translocation and activation of NFKB1. May also play an indirect role in activation of the non-canonical NF-kappa-B (NFKB2) pathway. In the signaling pathway leading to JUN activation, acts by phosphorylating the mediator STK39/SPAK and may not act through MAP kinases signaling. Plays a critical role in TCR/CD28-induced NFATC1 and NFATC2 transactivation by participating in the regulation of reduced inositol 1,4,5-trisphosphate generation and intracellular calcium mobilization. After costimulation of T-cells through CD28 can phosphorylate CBLB and is required for the ubiquitination and subsequent degradation of CBLB, which is a prerequisite for the activation of TCR. During T-cells differentiation, plays an important role in the development of T-helper 2 (Th2) cells following immune and inflammatory responses, and, in the development of inflammatory autoimmune diseases, is necessary for the activation of IL17-producing Th17 cells. May play a minor role in Th1 response.

Size: 100ul

Concentration: 1ug/ul

Applications: WB(1:300-5000)
ELISA(1:500-1000)
IHC-P(1:200-400)
IHC-F(1:100-500)
IF(IHC-P)(1:50-200)
IF(IHC-F)(1:50-200)
IF(ICC)(1:50-200)

Predicted Molecular Weight: 82


Cross Reactive Species: Human
Mouse

Predicted Cross Reactive Species: Rat
Dog

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • van Rees, Geertje Frederique, et al. "Evidence of microglial activation following exposure to serum from first-onset drug-naïve schizophrenia patients." Brain, Behavior, and Immunity (2017).Read more>>
VALIDATION IMAGES

Formalin-fixed and paraffin embedded human endometrial carcinoma labeled with Anti-phospho-PRKCQ(Thr538) Polyclonal Antibody, Unconjugated (bs-5585R) at 1:200 followed by conjugation to the secondary antibody


Lane 1: Mouse Cerebrum lysates; Lane 2: Mouse Cerebellum lysates probed with PRKCQ(Thr538) Polyclonal Antibody, Unconjugated (bs-5585R) at 1:1000 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.


Lane 1: Mouse Cerebrum tissue lysates; Lane 2: Mouse Cerebellum tissue lysates; Lane 3: Rat Cerebrum tissue lysates; Lane 4: Human HeLa cell lysates; Lane 5: Human K562 cell lysates; Lane 6: Human MOLT4 cell lysates probed with phospho-PRKCQ (Thr538) Polyclonal Antibody, Unconjugated (bs-5585R) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.